Barinthus Biotherapeutics plc (BRNS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Barinthus Biotherapeutics plc (BRNS) trades at $0.63 with AI Score 37/100 (Grade D). Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on innovative T-cell immunotherapies targeting chronic infectious diseases, autoimmune disorders, and various cancers. Market cap: $25.76M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for BRNS: BRNS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BRNS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BRNS: 1/1 perspectives are bearish.
How is this calculated? →Barinthus Biotherapeutics plc (BRNS) Healthcare & Pipeline Overview
Barinthus Biotherapeutics plc specializes in developing T-cell immunotherapies aimed at chronic infectious diseases and cancers, with a robust pipeline including candidates for Hepatitis B and HPV, positioning itself as a key player in the biopharmaceutical landscape.
What Is the Investment Thesis for BRNS?
Barinthus Biotherapeutics plc presents a unique investment thesis driven by its innovative drug pipeline and strategic focus on T-cell immunotherapies. The company is targeting significant market opportunities in chronic infectious diseases and cancers, with VTP-300 and VTP-200 addressing large patient populations. The global market for HBV treatments is projected to reach approximately $5 billion by 2028, while the HPV therapeutic market is expected to exceed $4 billion in the same timeframe. With a P/E ratio of -0.60 reflecting its clinical-stage status, Barinthus's growth potential hinges on successful clinical trials and regulatory approvals. The rebranding in 2023 signifies a renewed focus on its therapeutic advancements, positioning the company to capitalize on emerging healthcare needs. However, investors may want to evaluate the inherent risks associated with clinical-stage biopharmaceutical firms, including regulatory hurdles and market competition.
Based on FMP financials and quantitative analysis
BRNS Key Highlights
- Market Cap of $25.76M reflects the company's early-stage development status.
- P/E ratio of -0.60 indicates ongoing investment in R&D with no current earnings.
- Free Cash Flow (FCF) of -$0.02B highlights the need for funding to support clinical trials.
- Beta of -0.40 suggests lower volatility compared to the market, appealing to risk-averse investors.
- No dividend yield as Barinthus reinvests capital into its drug development pipeline.
Who Are BRNS's Competitors?
BRNS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| MRNA Moderna, Inc. | $81.80 | +2.56% | 33B | — |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| REGN Regeneron Pharmaceuticals, Inc. | $645.84 | -1.29% | $66.54B | 91 |
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BRNS's Key Strengths?
- Innovative drug pipeline with multiple candidates targeting significant health issues.
- Proprietary technology platforms enhancing drug development capabilities.
- Experienced management team with expertise in biopharmaceuticals.
- Strong focus on addressing unmet medical needs in chronic diseases and cancers.
What Are BRNS's Weaknesses?
- Currently in clinical stages with no approved products generating revenue.
- High dependency on successful clinical trial outcomes for future growth.
- Limited financial resources reflected in negative cash flow.
- Market competition from established biopharmaceutical companies.
What Are the Key Risks for BRNS?
- Financial-distress signal — its Altman Z-Score of -5.21 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-63.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What Are the Growth Opportunities for BRNS?
- Growth opportunity 1: Barinthus's VTP-300 candidate for chronic Hepatitis B is targeting a market projected to reach $5 billion by 2028. With approximately 257 million people affected globally, successful clinical trials could position the company as a leader in HBV treatment, enhancing its market share and revenue potential.
- Growth opportunity 2: The HPV therapeutic market is expected to exceed $4 billion by 2028, driven by increasing awareness and screening initiatives. Barinthus's VTP-200, aimed at treating persistent high-risk HPV, could tap into this lucrative market, especially as vaccination rates rise and more individuals seek effective treatments.
- Growth opportunity 3: The global market for autoimmune therapies is projected to grow significantly, with a focus on innovative treatments. Barinthus's VTP-1000, utilizing the SNAP-TI platform for celiac disease, addresses an unmet need in this space, potentially capturing a share of the growing autoimmune disorder treatment market.
- Growth opportunity 4: The recurrent prostate cancer market is expanding, with increasing incidences and a demand for effective therapies. Barinthus's VTP-850 aims to provide a next-generation immunotherapeutic solution, positioning the company to benefit from the projected growth in this therapeutic area.
- Growth opportunity 5: The preclinical candidate VTP-1100 for HPV-related cancers represents a significant growth opportunity as the incidence of HPV-related malignancies rises. With ongoing research and development, Barinthus could capitalize on this trend, potentially leading to a successful market entry within the next few years.
What Opportunities Does BRNS Have?
- Expanding global markets for chronic disease and cancer therapies.
- Potential partnerships and collaborations to enhance research and development.
- Increasing patient populations seeking innovative treatment options.
- Growing awareness and demand for effective immunotherapies.
What Threats Does BRNS Face?
- Regulatory challenges and lengthy approval processes for new therapies.
- Intense competition from larger, established biopharmaceutical firms.
- Market volatility impacting funding and investment opportunities.
- Rapid advancements in biotechnology potentially outpacing current developments.
What Are BRNS's Competitive Advantages?
- Proprietary platforms like SNAP-TI and SNAP-CI enhance the company's competitive edge in drug development.
- Focus on T-cell immunotherapies positions Barinthus in a niche market with high growth potential.
- Strong pipeline of experimental medicines addressing significant unmet medical needs in various therapeutic areas.
- Experienced leadership team with a track record in biopharmaceutical development and commercialization.
- Strategic partnerships and collaborations that enhance research capabilities and market access.
What Does BRNS Do?
Barinthus Biotherapeutics plc, founded in 2016 as Vaccitech plc, is a clinical-stage biopharmaceutical firm located in Didcot, UK. The company focuses on pioneering T-cell immunotherapies, leveraging the body's immune system to combat chronic infectious diseases, autoimmune disorders, and various cancers. In November 2023, the firm rebranded to reflect its commitment to innovative therapeutic solutions. Barinthus is advancing a diverse pipeline of experimental medicines, with VTP-300 as a flagship candidate targeting chronic Hepatitis B virus (HBV) infection, aiming for a functional cure. The company is also developing VTP-200, a non-surgical therapeutic for persistent high-risk human papillomavirus (HPV), and VTP-1000, which utilizes the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is designed to address recurrent prostate cancer, while VTP-1100 is in preclinical stages for HPV-related cancers. With a workforce of 105 employees, Barinthus is poised to make significant advancements in the biopharmaceutical sector, contributing to the treatment of diseases that have long challenged traditional therapies.
What Products and Services Does BRNS Offer?
- Develop T-cell immunotherapies targeting chronic infectious diseases, autoimmune disorders, and cancers.
- Advance a diverse pipeline of experimental medicines with a focus on innovative treatment solutions.
- Conduct clinical trials to evaluate the safety and efficacy of its therapeutic candidates.
- Utilize proprietary platforms like SNAP-TI and SNAP-CI for drug development.
- Engage in partnerships and collaborations to enhance research capabilities and market reach.
- Focus on addressing unmet medical needs in chronic diseases and cancer treatment.
How Does BRNS Make Money?
- Primarily generates revenue through the development and commercialization of innovative biopharmaceutical products.
- Engages in partnerships with other biopharmaceutical companies and research institutions to leverage expertise and resources.
- Secures funding through public and private investments to support clinical trials and R&D activities.
- Explores licensing agreements for its proprietary technologies and therapeutic candidates.
- Aims to achieve profitability through successful drug approvals and market entries.
What Industry Does BRNS Operate In?
The biotechnology industry is experiencing rapid growth, driven by advances in genetic research, personalized medicine, and immunotherapies. The global biopharmaceutical market is projected to reach $1.3 trillion by 2025, with a significant focus on innovative therapies for chronic diseases and cancers. Barinthus Biotherapeutics plc is positioned within this dynamic landscape, competing with other clinical-stage companies and established biopharmaceutical firms. The increasing prevalence of chronic diseases and the demand for effective treatments underscore the potential for growth in this sector, making Barinthus's focus on T-cell immunotherapies particularly relevant.
Who Are BRNS's Key Customers?
- Healthcare providers seeking innovative treatment options for chronic diseases and cancers.
- Patients affected by chronic infectious diseases and autoimmune disorders.
- Research institutions and pharmaceutical companies interested in collaboration and licensing opportunities.
- Investors looking for growth opportunities in the biopharmaceutical sector.
- Regulatory bodies involved in the approval and oversight of new therapeutic products.
How Barinthus Biotherapeutics plc Is Valued
Barinthus Biotherapeutics plc carries a market capitalization of $25.76M, placing it in the micro-cap category. Relative to its peer group, BRNS's quantitative score of 37/100 is below the peer average of 89/100.
Company Profile
Barinthus Biotherapeutics plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Didcot, GB. The company is led by CEO William James Enright. BRNS has traded publicly since 2021.
ROE -64%Key Financial Metrics
Return on equity for Barinthus Biotherapeutics plc stands at -63.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -56.7%, showing how much profit it generates from its asset base. A current ratio of 6.05 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -193.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Barinthus Biotherapeutics plc's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.21 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Barinthus Biotherapeutics plc revenue of about $739K for fiscal 2026, with EPS near $-1.37.
BRNS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Barinthus's pipeline, indicating potential breakthroughs ahead.
- Community sentiment has shifted positively, with discussions around upcoming product launches generating excitement.
- Analysts are highlighting the company's innovative approach to biotherapeutics, which could capture significant market share.
- Increased media coverage has raised awareness of Barinthus's advancements, attracting interest from new investors.
Bear Case
- Concerns about regulatory hurdles could slow down product approvals, leading to potential delays in revenue generation.
- Recent social sentiment shows skepticism regarding the company's ability to compete with established players in the biotherapeutics field.
- Market perception remains cautious due to the volatility in the biotech sector, which could impact investor confidence.
- Insider selling activity has raised red flags, leading some to question the long-term outlook for Barinthus.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BRNS Latest News
-
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga · Jun 8, 2026
-
Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
businesswire.com · May 11, 2026
BRNS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BRNS.
Price Targets
Wall Street price target analysis for BRNS.
BRNS MoonshotScore
What does this score mean?
The MoonshotScore rates BRNS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Barinthus Biotherapeutics plc ADR Information Sponsored
Barinthus Biotherapeutics plc (BRNS) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 2
- ADR Ratio: 1:1
Barinthus Biotherapeutics plc Healthcare Stock: Key Questions Answered
What are the key factors to evaluate for BRNS?
Barinthus Biotherapeutics plc (BRNS) holds an AI score of 37/100 (low). Not financial advice.
How frequently does BRNS data refresh on this page?
BRNS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BRNS's recent stock price performance?
Barinthus Biotherapeutics plc (BRNS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug pipeline with multiple candidates targeting significant health issues. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BRNS overvalued or undervalued right now?
Valuing Barinthus Biotherapeutics plc (BRNS) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BRNS?
Before investing in Barinthus Biotherapeutics plc (BRNS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BRNS to a portfolio?
Key strength of Barinthus Biotherapeutics plc (BRNS): Innovative drug pipeline with multiple candidates targeting significant health issues. Weigh rewards against risks and diversify. Not financial advice.
Can I buy fractional shares of BRNS?
Yes, most major brokerages offer fractional shares of Barinthus Biotherapeutics plc (BRNS) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BRNS's earnings and financial reports?
Barinthus Biotherapeutics plc (BRNS) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for BRNS earnings announcements is recommended.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.